Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.

Lymphoblast Oxidative Stress Genes as Potential Biomarkers of Disease Severity and Drug Effect in Friedreich's Ataxia.

There is no current approved therapy for the ultimately lethal neuro- and cardio-degenerative disease Friedreich's ataxia (FA). Finding minimally-invasive molecular biomarkers of disease progression and drug effect could support smaller, shorter clinical trials. Since we and others have noted a...

Descrizione completa

Dettagli Bibliografici
Autori principali:	Genki Hayashi, Gino Cortopassi
Natura:	Articolo
Lingua:	English
Pubblicazione:	Public Library of Science (PLoS) 2016-01-01
Serie:	PLoS ONE
Accesso online:	http://europepmc.org/articles/PMC4831832?pdf=render

Documenti analoghi

Sexual dimorphism in a mouse model of Friedreich’s ataxia with severe cardiomyopathy
di: Lili Salinas, et al.
Pubblicazione: (2024-10-01)

Potential biomarker identification for Friedreich's ataxia using overlapping gene expression patterns in patient cells and mouse dorsal root ganglion.
di: Marissa Z McMackin, et al.
Pubblicazione: (2019-01-01)

Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich's Ataxia.
di: Mittal Jasoliya, et al.
Pubblicazione: (2019-01-01)

Genetics and Friedreich Ataxia
di: J Gordon Millichap
Pubblicazione: (2002-06-01)

Genetics of Friedreich Ataxia
di: J Gordon Millichap
Pubblicazione: (1997-06-01)

Friedreich’s Ataxia: A Neuronal Point of View on the Oxidative Stress Hypothesis
di: Barbara Carletti, et al.
Pubblicazione: (2014-09-01)

Molecular Defects in Friedreich’s Ataxia: Convergence of Oxidative Stress and Cytoskeletal Abnormalities
di: Frances M. Smith, et al.
Pubblicazione: (2020-11-01)

Late-Onset Friedreich’s Ataxia
di: J Gordon Millichap
Pubblicazione: (1993-08-01)

Friedreich’s Ataxia with Retained Reflexes
di: J Gordon Millichap
Pubblicazione: (1995-04-01)

Friedreich's Ataxia and Glucose Metabolism
di: J Gordon Millichap
Pubblicazione: (1988-08-01)

5-Hydroxytryptophan in Friedreich’s Ataxia
di: J Gordon Millichap
Pubblicazione: (1995-06-01)

Iron Storage in Friedreich’s Ataxia
di: J Gordon Millichap
Pubblicazione: (1999-08-01)

Tissue Iron in Friedreich Ataxia
di: Arnulf H Koeppen
Pubblicazione: (2024-01-01)

Respiratory Function in Friedreich’s Ataxia
di: Elena Vinante, et al.
Pubblicazione: (2022-08-01)

The pathogenesis of cardiomyopathy in Friedreich ataxia.
di: Arnulf H Koeppen, et al.
Pubblicazione: (2015-01-01)

Is Friedreich ataxia an epigenetic disorder?
di: Kumari Daman, et al.
Pubblicazione: (2012-01-01)

Epigenetic modification of the frataxin gene for the treatment of Friedreich’s ataxia
di: Vilema Enriquez, MG
Pubblicazione: (2018)

Friedreich ataxia in a family from Mali, West Africa/Friedreich ataxia in a Malian family
di: Cheick A. K. Cissé, et al.
Pubblicazione: (2021-05-01)

Advantages and Limitations of Gene Therapy and Gene Editing for Friedreich’s Ataxia
di: Anusha Sivakumar, et al.
Pubblicazione: (2022-05-01)

Antioxidant Therapies and Oxidative Stress in Friedreich’s Ataxia: The Right Path or Just a Diversion?
di: Laura R. Rodríguez, et al.
Pubblicazione: (2020-07-01)

Impaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxia.
di: Vincent Paupe, et al.
Pubblicazione: (2009-01-01)

Exploring neuropsychiatric symptoms in Friedreich ataxia
di: Simona Karamazovova, et al.
Pubblicazione: (2024-11-01)

Friedreichs ataxia in a diabetic patient
di: Inna Igorevna Klefortova, et al.
Pubblicazione: (2010-06-01)

Friedreich's Ataxia – A Clinical Diagnosis
di: Md. Fekarul Islam, et al.
Pubblicazione: (2015-01-01)

Clinical and Genetic Diagnosis of Friedreich’s Ataxia
di: J Gordon Millichap
Pubblicazione: (1998-05-01)

Emerging antioxidant therapies in Friedreich’s ataxia
di: Fred Jonathan Edzeamey, et al.
Pubblicazione: (2024-02-01)

An Overview of the Ferroptosis Hallmarks in Friedreich’s Ataxia
di: Riccardo Turchi, et al.
Pubblicazione: (2020-10-01)

Perspectives on current models of Friedreich’s ataxia
di: Simge Kelekçi, et al.
Pubblicazione: (2022-08-01)

Anaesthesia for a patient with Friedreich′s ataxia
di: Ilango Ganesan
Pubblicazione: (2011-01-01)

Otoneurological Abnormalities in Patients with Friedreich's Ataxia
di: Bianca Simone Zeigelboim, et al.
Pubblicazione: (2017-01-01)

Epigenetic-based therapies for Friedreich ataxia
di: Chiranjeevi eSandi, et al.
Pubblicazione: (2014-06-01)

Predictors of loss of ambulation in Friedreich's ataxia
di: Christian Rummey, et al.
Pubblicazione: (2020-01-01)

Hepatic mitochondrial dysfunction in Friedreich Ataxia
di: Stüwe Sven H, et al.
Pubblicazione: (2011-11-01)

Prediction of the disease course in Friedreich ataxia
di: Christian Hohenfeld, et al.
Pubblicazione: (2022-11-01)

Friedreich’s Ataxia-A Case Report
di: Tahreem Muntaha, et al.
Pubblicazione: (2018-11-01)

Friedreich ataxia- pathogenesis and implications for therapies
di: Martin B. Delatycki, et al.
Pubblicazione: (2019-12-01)

At-home wearable-based monitoring predicts clinical measures and biological biomarkers of disease severity in Friedreich’s Ataxia
di: Ram Kinker Mishra, et al.
Pubblicazione: (2024-10-01)

Perspectives of the Friedreich ataxia community on gene therapy clinical trials
di: Shandra J. Trantham, et al.
Pubblicazione: (2024-03-01)

Estrogen prevents oxidative damage to the mitochondria in Friedreich's ataxia skin fibroblasts.
di: Timothy E Richardson, et al.
Pubblicazione: (2012-01-01)

Novel Nrf2-Inducer Prevents Mitochondrial Defects and Oxidative Stress in Friedreich’s Ataxia Models
di: Rosella Abeti, et al.
Pubblicazione: (2018-07-01)